Comment on "pP2A inhibition sensitizes cancer stem cells to ABL tyrosine kinase inhibitors in BCR-ABL human leukemia"

Author
Perrotti, D.
Agarwal, A.
Lucas, C.M.
Date
2019
Journal
Science Translational Medicine
Publisher
American Association for the Advancement of Science
Type
Article

Metadata
Show full item record
See at
https://www.doi.org/10.1126/scitranslmed.aau0416
Abstract
LB100 does not sensitize CML stem cells to tyrosine kinase inhibitor-induced apoptosis. Copyright 2019 The Authors.
Keyword
Leukemia
Neoplastic Stem Cells
Identifier to cite or link to this item
https://www.scopus.com/inward/record.uri?eid=2-s2.0-85069912263&doi=10.1126%2fscitranslmed.aau0416&partnerID=40&md5=4dbc1da010bf94217da9296cc4c89105; http://hdl.handle.net/10713/10369
Collections